Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is the next evolution ...
Guggenheim analyst Vamil Divan maintained a Buy rating on Insmed today and set a price target of $230.00. Claim 55% Off TipRanks. Unlock hedge fund-level data and powerful investi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results